PainChek General Discussion, page-8469

While it has since retreated to 22c, Canaccord Genuity initiated coverage last week and set a price target of 55c.

“While PCK is in its early commercialisation phase, even revenue multiples don’t do justice to an assessment of the potential for this business,” Canaccord’s Martyn Jacobs said.

“This unique technology provides a breakthrough to an intractable problem in the aged care sector which is in desperate need of technological solutions to support the care of the elderly and particularly those living with dementia.”

Among predicted catalysts for growth were the expansion of the technology to infants as well as US FDA clearance.